Answers are grounded in this paper and cite their sources.
New therapeutic modalities for melanoma promise benefit in selected individuals. Efficacy appears greater in patients with lower tumor burden, suggesting an important role for risk-stratified surveillance. Robust predictive markers might permit optimization of agent to patient, while low-risk prognostic markers might guide more conservative management. This review evaluates protein, gene, and multiplexed marker panels that may contribute to better risk assessment and improved management of patients with cutaneous melanoma.
No takes yet. Share an insight, caveat, or question.
Hyams et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: